Clinical trials: Influenza in Humans
Vaccination; Infection
Mood and Influenza Vaccine Response: A Feasibility Trial
This study is a 2-arm, parallel, randomised controlled feasibility trial of a brief video intervention designed to induce positive affect (mood) in older adults in primary care settings prior to the receipt of influenza…
- Trial name
- NCT03144518
- Testing
- Positive Affect Intervention, Neutral Control Intervention, Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
- Where
- United Kingdom
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Influenza, Human
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an…
- Trial name
- NCT03314662
- Testing
- MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1), MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)
- Where
- 20 sites in United States
- Volunteers
- 1,778 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Orthomyxovirus Infection
Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
This is a multi-center study designed to evaluate the safety and immunogenicity of a Fluzone revaccination in elderly adults aged ≥ 65 years. Primary Objective: To describe the safety profile for all subjects.
- Conditions
- Influenza, Orthomyxovirus Infection, Myxovirus Infection
- Trial name
- NCT00775450
- Testing
- Influenza Virus Vaccine USP Trivalent Types A and B
- Where
- 28 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
The study will evaluate the safety and immunogenicity of the 2015-2016 formulation of Fluzone Quadrivalent vaccine, administered in a 1- or 2-dose schedule, in accordance with the Advisory Committee on Immunization Practices…
- Trial name
- NCT02539108
- Testing
- Fluzone® Quadrivalent Influenza Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home
We hypothesize that when offered influenza vaccine at little or no cost, in a setting where the value of the vaccine is connected to one's high risk child, vaccination rates for parents will approach 90-95%, similar to rates…
- Trial name
- NCT00812110
- Testing
- Influenzae vaccine
- Where
- United States
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Akron Children's Hospital
Vaccine Response
Systems Biological Assessment of Statin Effect on Vaccine Responses
This study is being done to answer the question: Does the use of statin lipid-lowering medication change the effect of influenza vaccine? The research team will use the knowledge gained from answering this question to understand…
- Trial name
- NCT06024096
- Testing
- Atorvastatin, Quadrivalent seasonal influenza vaccine
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Emory University
Asthma
Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma
This is a randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of a fixed dose of benralizumab administered subcutaneously (SC) on antibody responses following seasonal…
- Trial name
- ALIZE (NCT02814643)
- Testing
- Benralizumab, Seasonal influenza virus vaccine
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Influenza
A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults
This study will assess the Efficacy, Safety and Tolerability profile of CSL's Influenza Vaccine administered intramuscularly against laboratory-confirmed influenza illness in a population defined as being not at risk of severe…
- Trial name
- CSL's IVV (NCT00562484)
- Testing
- CSL Limited Influenza Vaccine
- Where
- 24 sites in Australia, New Zealand
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Effect of Oseltamivir on Cognitive Function in Subjects With Influenza
This study has been designed to determine if subjects treated with oseltamivir in addition to standard of care treatment for influenza demonstrate a greater improvement in attention / working memory / processing speed / mood as…
- Trial name
- FOCUS (NCT01249833)
- Testing
- Oseltamivir
- Where
- 16 sites in Canada
- Volunteers
- 122 people
- Sponsor
- Trial Management Group Inc.
Influenza
Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.
The purpose of this study is to evaluate the safety and immunogenicity of GSK influenza vaccine candidate compared to a licensed trivalent influenza vaccine in adults.
- Trial name
- NCT00714285
- Testing
- GSK Biologicals' quadrivalent influenza vaccine, GSK Biologicals' trivalent influenza vaccine
- Where
- Czechia
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009
This study will compare influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT01987349
- Testing
- Fluzone® (intramuscular), FluMist® (intranasal)
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Stanford University
Herpes Zoster
Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)
The study evaluated immunogenicity, safety, and tolerability of ZOSTAVAX™ Vaccine (V211) administered concomitantly versus nonconcomitantly with Quadrivalent Influenza Virus vaccine (inactivated) in participants ≥50 years of age.
- Trial name
- NCT02519855
- Testing
- ZOSTAVAX™, Influenza Vaccine
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects
One in three Americans are obese. Obese subjects may or may not need higher doses of the anti-flu drug known as Tamiflu (oseltamivir).
- Trial name
- NCT01179919
- Testing
- Oseltamivir
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Manjunath Prakash Pai
Influenza
Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers
The purpose of this study is to assess the humoral immune response and safety of the parenteral formulation of the 2010/2011-season virosomal subunit influenza vaccine Inflexal V using two different HA antigen suppliers (AdImmune…
- Trial name
- NCT01412281
- Testing
- Virosomal influenza vaccine (AdImmune HA Antigen), Virosomal influenza vaccine (CSL HA Antigen)
- Where
- Switzerland
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza, Respiratory Tract Infections
Patient Portal Flu Vaccine Reminders_RCT 4
This trial is taking place in Los Angeles, CA at clinics within the UCLA Health System. The study design is a 2x2 nested factorial design.
- Trial name
- NCT05052190
- Testing
- Text Message R/R with Direct Appointment Schedule Link, Text Message R/R without Direct Appointment Schedule Link, Text Pre-Appointment Reminder
- Where
- United States
- Volunteers
- 239,567 people
- Sponsor
- University of California, Los Angeles
Influenza
Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults
Background: The flu is a common viral infection that can be deadly for certain people. Vaccines against flu have been developed to teach the body to prevent or fight the infection.
- Trial name
- NCT04579250
- Testing
- VRC-FLUNPF0103-00-VP (H10ssF-6473)
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)